Chemists at Université de Montréal have developed "signaling cascades" made with DNA molecules to report and quantify the ...

Circulating tumor DNA (ctDNA)—genetic material shed from tumors into the bloodstream—may help risk-stratify patients with ...

EG110A received FDA fast track designation to treat neurogenic detrusor overactivity, a bladder issue common in MS.

Faulty versions of the LMNA gene can cause a wide range of health problems, including heart muscle disease (dilated ...

MIAMI, FLORIDA (OCT. 20, 2025) – A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors ...

Inspired by living cells, researchers have designed DNA molecules that allow drug concentrations in blood to be measured ...

New gene-editing project targets thalassemia’s root cause A new research project at the Cyprus Institute of Neurology and ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

New research found that gene therapy for children with a form of severe combined immunodeficiency was successful in 95% of ...

According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...

French biotech EG 427 has had success with its urinary incontinence DNA therapy, EG110A, showing a more than 80% reduction in episodes. In the Phase Ib/IIa trial (NCT06596291), the lowest dose of ...